Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource.


Journal

Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310

Informations de publication

Date de publication:
12 Jun 2020
Historique:
received: 11 12 2019
revised: 25 02 2020
accepted: 01 03 2020
pubmed: 10 3 2020
medline: 14 1 2021
entrez: 10 3 2020
Statut: ppublish

Résumé

An extensive ethnopharmacological survey was carried out in the Peruvian Amazonian district of Loreto with informants of various cultural origins from the surroundings of Iquitos (capital city of Loreto) and from 15 isolated riverine Quechua communities of the Pastaza River. A close attention was paid to the medical context and plant therapy, leading to the selection of 35 plant species (45 extracts). The extracts were tested for antiviral activity against HCV with counting of Huh-7 cellular death in case of toxicity, and cytotoxicity was evaluated in HepG2 cells. The aim of the study was to inventory the plants used against hepatitis in Loreto, then to evaluate their antiviral activity and to suggest a way to improve local therapeutic strategy against viral hepatitis, which is a fatal disease that is still increasing in this area. An ethnographic survey was carried out using "participant-observation" methodology and focusing on plant therapy against hepatitis including associated remedies. 45 parts of plant were extracted with methanol and tested in vitro for anti-HCV activity in 96-well plate, using HCV cell culture system with immunofluorescent detection assisted by automated confocal microscopy. Toxicity of plant extracts was also evaluated in microplates on hepatic cells by immunofluorescent detection, for the Huh-7 nuclei viability, and by UV-absorbance measurement of MTT formazan for cytotoxicity in HepG2 cells. In vitro assay revealed interesting activity of 18 extracts (50% infection inhibition at 25 μg/mL) with low cytotoxicity for 15 of them. Result analysis showed that at least 30% of HCV virus were inhibited at 25 μg/mL for 60% of the plant extracts. Moreover, the ethnomedical survey showed that remedies used with low and accurate dosing as targeted therapy against hepatitis are usually more active than species indicated with more flexible dosing to alleviate symptoms of hepatic diseases. Together with bibliographic data analysis, this study supported the traditional medicinal uses of many plants and contributed to a better understanding of the local medical system. It also permitted to refine the therapeutic plant indications regarding patients' liver injuries and vulnerability. Only 2 of the 15 most active plant species have already been studied for antiviral activity against hepatitis suggesting new avenues to be followed for the 13 other species.

Identifiants

pubmed: 32147478
pii: S0378-8741(19)34930-X
doi: 10.1016/j.jep.2020.112735
pii:
doi:

Substances chimiques

Antiviral Agents 0
Plant Extracts 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112735

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no conflict of interest.

Auteurs

Vincent Roumy (V)

Univ. Lille, INRA, YNCREA, Univ. Artois, Univ. Littoral Côte d'Opale, EA 7394-ICV-Institut Charles Viollette, F-59000, Lille, France. Electronic address: vincent.roumy@univ-lille.fr.

Lastenia Ruiz (L)

Laboratorio de Investigación de Productos Naturales Antiparasitarios de la Amazonia (LIPNAA), Universidad Nacional de la Amazonía Peruana (UNAP), Centro de Investigaciones de Recursos Naturales de la Amazonía (CIRNA), Nuevo San Lorenzo, Iquitos, Perú.

Juan Celidonio Ruiz Macedo (JC)

Herbarium de la Amazonía Peruana Amazonense de la Universidad Nacional de la Amazonía Peruana (UNAP), Nanay con Pevas, Iquitos, Perú.

Andrea-Luz Gutierrez-Choquevilca (AL)

Ecole Pratique des Hautes Etudes, EPHE PSL, Laboratoire d'anthropologie sociale (UMR 7130, Collège de France, 75005, Paris France).

Jennifer Samaillie (J)

Univ. Lille, INRA, YNCREA, Univ. Artois, Univ. Littoral Côte d'Opale, EA 7394-ICV-Institut Charles Viollette, F-59000, Lille, France.

Leonor Arévalo Encinas (LA)

Laboratorio de Investigación de Productos Naturales Antiparasitarios de la Amazonia (LIPNAA), Universidad Nacional de la Amazonía Peruana (UNAP), Centro de Investigaciones de Recursos Naturales de la Amazonía (CIRNA), Nuevo San Lorenzo, Iquitos, Perú.

Wilfredo Ruiz Mesia (WR)

Laboratorio de Investigación de Productos Naturales Antiparasitarios de la Amazonia (LIPNAA), Universidad Nacional de la Amazonía Peruana (UNAP), Centro de Investigaciones de Recursos Naturales de la Amazonía (CIRNA), Nuevo San Lorenzo, Iquitos, Perú.

Hivelli Ericka Ricopa Cotrina (HE)

Laboratorio de Investigación de Productos Naturales Antiparasitarios de la Amazonia (LIPNAA), Universidad Nacional de la Amazonía Peruana (UNAP), Centro de Investigaciones de Recursos Naturales de la Amazonía (CIRNA), Nuevo San Lorenzo, Iquitos, Perú.

Céline Rivière (C)

Univ. Lille, INRA, YNCREA, Univ. Artois, Univ. Littoral Côte d'Opale, EA 7394-ICV-Institut Charles Viollette, F-59000, Lille, France.

Sevser Sahpaz (S)

Univ. Lille, INRA, YNCREA, Univ. Artois, Univ. Littoral Côte d'Opale, EA 7394-ICV-Institut Charles Viollette, F-59000, Lille, France.

Simon Bordage (S)

Univ. Lille, INRA, YNCREA, Univ. Artois, Univ. Littoral Côte d'Opale, EA 7394-ICV-Institut Charles Viollette, F-59000, Lille, France.

Guillaume Garçon (G)

Univ. Lille, CHU Lille, Institut Pasteur de Lille, EA 4483-IMPECS-IMPact de l'Environnement Chimique sur la Santé humaine, F-59000, Lille France.

Jean Dubuisson (J)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL, Center for Infection and Immunity of Lille, F-59000 Lille, France.

Sebastien Anthérieu (S)

Univ. Lille, CHU Lille, Institut Pasteur de Lille, EA 4483-IMPECS-IMPact de l'Environnement Chimique sur la Santé humaine, F-59000, Lille France.

Karin Seron (K)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL, Center for Infection and Immunity of Lille, F-59000 Lille, France.

Thierry Hennebelle (T)

Univ. Lille, INRA, YNCREA, Univ. Artois, Univ. Littoral Côte d'Opale, EA 7394-ICV-Institut Charles Viollette, F-59000, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH